[1] |
XU Z, XIE H, ZHOU L, et al. The combination strategy of transarterial chemoembolization and radiofrequency ablation or microwave ablation against hepatocellular carcinoma[J]. Anal Cell Pathol (Amst), 2019, 2019: 8619096.
|
[2] |
HRISTOVSKA A M, DUCH P, ALLINGSTRUP M, et al. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults[J]. Cochrane Database Syst Rev, 2017, 8(8):CD012763.
|
[3] |
ZOREMBA N, SCHÄLTE G, BRUELLS C, et al. Update on muscle relaxation : what comes after succinylcholine, rocuronium and sugammadex?[J]. Anaesthesist, 2017, 66(5):353-359.
doi: 10.1007/s00101-017-0289-1
URL
|
[4] |
DHIR M, MELIN A A, DOUAIHER J, et al. A review and update of treatment options and controversies in the management of hepatocellular carcinoma[J]. Ann Surg, 2016, 263(6):1112-1125.
doi: 10.1097/SLA.0000000000001556
pmid: 26813914
|
[5] |
GRABACKA M, WALIGORSKI P, ZAPATA A, et al. Fenofibrate subcellular distribution as a rationale for the intracranial delivery through biodegradable carrier[J]. J Physiol Pharmacol, 2015, 66(2):233-247.
pmid: 25903954
|
[6] |
PAN T, XIE Q K, LV N, et al. Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: a propensity score-matching analysis[J]. Radiology, 2017, 282(1):259-270.
doi: 10.1148/radiol.2016151807
pmid: 27399327
|
[7] |
ZHAO Q, WANG L, CHEN F, et al. Percutaneous radiofrequency ablation for treatment of giant cell tumor of bone guided by real-time US fused with CT[J]. J Med Ultrason(2001), 2014, 41(2):223-227.
doi: 10.1007/s10396-013-0482-z
URL
|
[8] |
CAMMU G, CODDENS J, HENDROCKX J, et al. Dose requirements of infusions of cisatracurium or rocuronium during hypothermic cardiopulmonary bypass[J]. Br J Anaesth, 2000, 84(5):587-590.
doi: 10.1093/bja/84.5.587
URL
|
[9] |
中华医学会外科学分会, 中华医学会麻醉学分会. 中国加速康复外科临床实践指南(2021二)[J]. 协和医学杂志, 2021, 12(5):632-640.
|
|
Surgery Society of Chinese Medical Association, Anesthesiology Society of Chinese Medical Association. Clinical Practice Guidelines for ERAS in China (2021)(Ⅱ)[J]. Med J PUMCH, 2021, 12(5):632-640.
|
[10] |
KAYE A D, KAYE R J, CORNETT E M, et al. The role of sugammadex, a novel cyclodextrin compound in mo-dern anesthesia practice: conventional neuromuscular physiology and clinical pharmacology[J]. Expert Rev Clin Pharmacol, 2019, 12(10):917-919.
doi: 10.1080/17512433.2019.1659134
URL
|
[11] |
MCDONAGH D L, BENEDICT P E, KOVAC A L, et al. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients[J]. Anesthesiology, 2011, 114(2):318-329.
doi: 10.1097/ALN.0b013e3182065c36
pmid: 21239968
|
[12] |
CARRON M, LINASSI F, DE CASSAI A. Role of sugammadex in accelerating postoperative discharge: an updated meta-analysis[J]. J Clin Anesth, 2020, 65:109895.
doi: 10.1016/j.jclinane.2020.109895
pmid: 32464475
|
[13] |
HRISTOVSKA A M, DUCH P, ALLINGSTRUP M, et al. The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis[J]. Anaesthesia, 2018, 73(5):631-641.
doi: 10.1111/anae.14160
pmid: 29280475
|
[14] |
HERRING W J, WOO T, ASSAID C A, et al. Sugammadex efficacy for reversal of rocuronium- and vecuronium-induced neuromuscular blockade: a pooled analysis of 26 studies[J]. J Clin Anesth, 2017, 41:84-91.
doi: S0952-8180(17)30302-1
pmid: 28802619
|
[15] |
CRAIG R G, HUNTER J M. Neuromuscular blocking drugs and their antagonists in patients with organ disease[J]. Anaesthesia, 2009, 64(Suppl 1):55-65.
doi: 10.1111/ana.2009.64.issue-s1
URL
|
[16] |
FUJITA A, ISHIBE N, YOSHIHARA T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery[J]. Acta Anaesthesiol Taiwan, 2014, 52(2):54-58.
doi: 10.1016/j.aat.2014.04.007
pmid: 25016508
|
[17] |
JEONG H, TANATPORN P, AHN H J, et al. Pressure support versus spontaneous ventilation during anesthetic emergence-effect on postoperative atelectasis: a rando-mized controlled trial[J]. Anesthesiology, 2021, 135(6):1004-1014.
doi: 10.1097/ALN.0000000000003997
URL
|
[18] |
LI G, FREUNDLICH R E, GUPTA R K, et al. Postoperative pulmonary complications’ association with sugammadex versus neostigmine: a retrospective registry analysis[J]. Anesthesiology, 2021, 134(6):862-873.
doi: 10.1097/ALN.0000000000003735
URL
|
[19] |
KHETERPAL S, VAUGHN M T, DUBOVOY T Z, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): a multicenter matched cohort analysis[J]. Anesthesiology, 2020, 132(6):1371-1381.
doi: 10.1097/ALN.0000000000003256
URL
|
[20] |
KRAUSE M, MCWILLIAMS S K, BULLARD K J, et al. Neostigmine versus sugammadex for reversal of neuromuscular blockade and effects on reintubation for respiratory failure or newly initiated noninvasive ventilation: an interrupted time series design[J]. Anesth Analg, 2020, 131(1):141-151.
doi: 10.1213/ANE.0000000000004505
URL
|
[21] |
ABAD-GURUMETA A, RIPOLLÉS-MELCHOR J, CASANS-FRANCÉS R, et al. A systematic review of sugammadex vs. neostigmine for reversal of neuromuscular blockade[J]. Anaesthesia, 2015, 70(12):1441-1452.
doi: 10.1111/anae.2015.70.issue-12
URL
|